Clinical Development of Psychedelic Therapies

Clinical development for psychedelic therapies is moving from early promise into harder access questions. Developers need evidence that can satisfy regulators, payers, clinicians, and health systems, not only a positive trial headline.

The hard design choices are practical: who is enrolled, what the treatment is compared against, how blinding is handled, which outcomes matter, how long patients are followed, and how psychological support is described. Those choices shape both approval and reimbursement.

This page focuses on the decisions that matter before late-stage trials are locked. It covers trial design, regulatory engagement, manufacturing and distribution, stakeholder coordination, and the evidence package needed for European access.

Build trials for approval and access

The design choices that decide whether evidence travels

Blinding and placebo control

Blinding, also called masking, means keeping participants, clinicians, and assessors from knowing which treatment was given. It reduces bias, but psychedelic trials make this harder because the active drug can produce noticeable psychoactive effects.

The problem is measurable. In one Phase III MDMA therapy trial for PTSD, 79% of participants in the MDMA group correctly guessed they had received the active drug, compared with 16% in the placebo group. In a single-blind psilocybin depression study, 80% of participants correctly identified psilocybin or placebo.

Unblinding affects many psychotropic-drug trials, not only psychedelic studies. A systematic review found that masking efficacy is often unreported or poorly tested in psychotherapy and pharmacology trials, with unblinding detected in a majority of cases when assessed (Boutron et al., 2006). For example, only 59% of psychiatric trials published in top journals in 2017 and 2018 adequately reported masking outcomes (Juul et al., 2021).

Expectancy adds another layer. If participants believe they received the active treatment, that belief can affect outcomes. If they believe they received placebo, disappointment can also affect response. Payers and regulators therefore need to know how expectancy was measured and handled.

Placebo response is not only a psychedelic issue. Social contact, care intensity, trial setting, and cultural expectations can all change outcomes. That is why the support model has to be described clearly instead of treated as background noise.

Researchers can reduce functional unblinding with active placebos, low-dose comparators, independent raters, expectation measures, and sensitivity analyses. Each option has trade-offs, so the design has to explain what question it can and cannot answer.

Cybin's Phase III CYB003 design offers one example. Dosing monitors collect session-experience data, while outcome raters and other site staff are kept away from those data. The aim is to reduce the chance that subjective drug effects influence outcome assessment.

Even with these steps, functional unblinding remains a live concern. Future trials should report unblinding surveys, expectancy measures, subgroup analyses, and sensitivity checks so reviewers can judge how much the trial result depends on the drug, the setting, and participant expectations.

Comparator selection

Comparator choice shapes whether a psychedelic trial can answer both regulatory and payer questions. A study may compare the therapy with standard care, placebo, psychotherapy, or another active treatment. The closer the comparator is to real clinical practice, the easier it is for HTA bodies and payers to judge added value after approval.

Current comparator strategies in psychedelic trials

Many psychedelic trials compare the investigational therapy with placebo or with a lower dose of the same drug. That design can help isolate drug effect and reduce some unblinding problems, but it often leaves payers asking a different question: how does this compare with care patients already receive?

Head-to-head evidence is still limited in the psychedelic field. Esketamine offers one useful precedent: a Phase IIIb study compared Spravato with extended-release quetiapine in treatment-resistant depression, with both groups continuing standard antidepressants (Reif et al., 2023).

Emerging psychedelic programmes have taken different routes. Usona's Phase III psilocybin trial uses inactive placebo, 5 mg psilocybin, and 25 mg psilocybin groups (NLM, 2024-2026). MDMA therapy trials used specialised therapy protocols but avoided low-dose comparators (Mitchell et al., 2021; FDA, 2024).

Some trials minimise the therapy component to present psychedelics as more drug-led interventions, which can simplify regulatory and payer assessment (NLM, 2023-2025). The tradeoff is interpretability: if psychological support is reduced too far, the trial may no longer reflect the care model that patients and providers expect.

The access gap is clear: few studies compare psychedelic therapies directly with the standard treatments payers already fund, such as SSRIs for depression or CBT for anxiety disorders. Without those comparisons, HTA bodies must infer relative value from indirect evidence.

Regulatory and HTA requirements for comparators

Regulators and payers ask related but different questions. FDA and EMA approval can rest on placebo-controlled evidence if safety, efficacy, and quality standards are met. HTA bodies then ask whether the treatment adds enough value compared with current care to justify coverage, price, staffing, and service redesign (FDA, 2001; EP, 2021).

Examples of head-to-head comparisons and challenges

Few psychedelic trials have made direct comparisons with established medicines. One study compared psilocybin with the SSRI escitalopram in people with moderate-to-severe depression (Carhart-Harris et al., 2021). Psilocybin performed better on several secondary measures, including HAM-D-17, MADRS, remission, and quality of life, but the primary QIDS-SR-16 outcome did not separate statistically. A six-month follow-up found sustained benefits in both groups, while also noting limits such as low statistical power and reliance on self-reported outcomes (Erritzoe et al., 2024).

Direct comparisons are expensive and difficult, especially for treatments that require controlled drugs, trained therapists, longer visits, and specialised rooms. They can also increase unblinding if the comparator feels very different from the psychedelic session. Even so, avoiding them entirely can push the hardest access questions into the reimbursement stage.

Regional variations in comparator expectations

Comparator expectations differ by country. The Netherlands emphasises productivity effects and comparative effectiveness. Germany's IQWiG places more weight on direct comparisons with standard treatment, because indirect comparisons are often hard to interpret. Czech HTA processes are less formalised but increasingly align with EU expectations. NICE in England and Wales evaluates against current standard of care and may accept indirect comparisons in some cases.

Comparator strategy for access

Head-to-head trials are valuable for HTA and reimbursement, but they are not the only option in every setting. Network meta-analyses can sometimes compare interventions indirectly using existing data, though the result depends on trial comparability and assumptions. Early HTA engagement helps developers decide where direct comparison is essential and where another evidence route may be acceptable.

As psychedelic trials advance, comparators should reflect real clinical practice where possible.[13] The access question is not only whether a treatment beats placebo; it is whether payers can see what care it would replace, for which patients, and at what cost.[13]1 Future research should prioritise cost-effective study designs that address these gaps while maintaining the therapeutic integrity of psychedelic treatments.

Integration of psychotherapy

Psychedelic trials need to define what is being tested: the drug alone, the drug plus structured psychological support, or a broader therapy model. Developers may try to standardise or reduce the psychotherapy component to lower cost, simplify operations, and fit drug-centred regulatory systems. Many clinicians, however, view preparation, support, and integration as part of the treatment itself. That tension affects trial design, outcomes, reimbursement arguments, and clinical acceptance.

Is therapy part of the treatment or part of the setting?

Clinical teams still disagree about how central psychotherapy is to psychedelic treatment. Traditional protocols include preparation, dosing, and integration sessions. MDMA therapy researchers have argued that a strong therapeutic alliance helps participants during altered states and supports later processing (O'Donnell et al., 2024). Psilocybin trials have also used structured preparation, dosing, and integration to help patients make sense of difficult experiences (Phelps, 2017).

Some developers are testing leaner support models. Compass Pathways and MindMed have reported responses with more limited therapeutic intervention, including rapid effects after dosing in some responder analyses (Goodwin et al., 2023; Goodwin et al., 2024; Holze et al., 2023). Leaner models could make access easier, but the field still needs to know which patients need more support, who can safely receive less, and how those choices affect outcomes (Goodwin et al., 2023; Grunder et al., 2024).

The practical question is how much support is needed for safe, effective care. More intensive therapy may help some patients, but it also raises staffing, reimbursement, and infrastructure demands. Trials and implementation studies need to show how different support models affect outcomes, cost, safety, and access.

Standardisation and variability across sites

Multi-site trials also need consistent therapy delivery. Intensive models, including the Lykos MDMA therapy protocol, allow several therapeutic methods while asking teams to follow a shared framework. Independent monitoring found strong adherence to elements such as trauma-focused care and relational skill. Some variation remains, especially across countries and cultures, but the available evidence suggests that structured training and monitoring can keep delivery consistent enough for clinical study (O'Donnell et al., 2024).

Companies such as Compass Pathways and MindMed have tested protocols with less psychotherapeutic support, which can make site participation and implementation easier. The access question is what is lost when support is reduced: treatment effect, safety, adherence, or generalisability across ordinary clinical settings (Cavarra et al., 2022).

Therapy or attention?

Another unresolved question is whether outcomes come from a specific therapy method or from attention, trust, time, and support. Some psilocybin depression trials show meaningful improvement in placebo groups that receive the same therapist contact (Grunder et al., 2024). That makes it harder to separate drug effect, therapy effect, and the broader care environment.

Patients also point to support after the trial. Peer groups, informal check-ins, and additional therapy may help sustain gains, but these supports are rarely measured in trial outcomes. If they matter, payers need to know whether they are optional extras or part of the real cost of care.

What development can settle now

Trials do not need to settle every philosophical debate about psychotherapy. They do need to define the support model clearly, measure whether it is delivered consistently, and show which parts are needed for safety and effect. Without that, regulators may approve a medicine while payers and providers remain unsure what service they are being asked to fund (Aday et al., 2024).

The industry's use of terms such as "psychoplastogens" reflects a stronger focus on neurobiology and mechanism (EFPIA, 2024b). That evidence can help explain how a treatment works, but access cases still need patient-relevant outcomes: function, quality of life, relapse, and sustained benefit.

After initial approvals, much of the delivery-model work may be better suited to clinical researchers, professional bodies, and health systems than to drug developers alone. Developers still need to prove safety and efficacy. Later studies and clinical guidelines can refine which elements of psychological support, relational care, and integration matter most in practice.

Controlled-substance rules still shape development

Drug-control rules still affect psychedelic research. Many classic psychedelics sit under strict national controls linked to the 1971 UN Convention on Psychotropic Substances. That status can slow licensing, storage, import, prescribing, and commercial planning even when clinical research is allowed (UN, 1971; Demireva & Brun, 2023).

The EU Clinical Trials Regulation has harmonised many parts of drug development across Europe, but controlled-substance requirements remain national. Sponsors still need country-by-country permissions, pharmacy controls, and handling procedures before trial sites can operate (EU, 2014).

Regulation is starting to move. Australia rescheduled psilocybin and MDMA for specific psychiatric use under authorised prescribers (TGA, 2023). In Europe, a successful marketing authorisation would likely require changes to the approved drug product's control status, which could make later research, prescribing, and access easier (Haberkamp, 2024).

Who gets studied determines who can get access

Defining target populations

Patient selection is not just a recruitment decision. It determines which claims a developer can make, which safety questions remain open, how large the eligible population looks, and whether payers can apply the results to real services.

Balance precision with real-world relevance

Many trials focus on treatment-resistant depression, chronic PTSD, or other high-need groups. That makes sense: unmet need can support approval, pricing, and reimbursement discussions. It also matches where many European systems are likely to start if psychedelic therapies enter routine care (Sabe et al., 2024).

Broader trial populations can make recruitment easier and may produce higher response rates. They can also make effects look smaller if participants have milder symptoms and less room to improve. In routine care, clinicians are unlikely to offer psychedelic therapies before established treatments. European regulators, payers, and clinicians will probably start with narrower groups who have limited options, such as treatment-resistant patients.

Very narrow criteria can make a trial cleaner but less useful for access. The EPIsoDE study, for example, excluded some patients with comorbid conditions or recent psychedelic use to make the study easier to interpret (Mertens et al., 2022). That helps answer the efficacy question, but it leaves health systems asking how results apply to more complex patients.

Comorbidities and real-world complexity

Many psychedelic trials exclude people with common comorbidities, including depression with anxiety, addiction, or other psychiatric conditions. This reduces variability in a study, but it also moves the trial population away from real care, where overlapping conditions are common (van Elk & Fried, 2023). One analysis found that applying typical trial exclusions could rule out up to 99% of people with depression, raising doubts about how well trial findings transfer to practice (Zimmerman et al., 2005).

Future studies should show where broader inclusion is safe. Allowing stable comorbidities, adding pragmatic extension studies, or using adaptive designs could make results more useful for care while preserving the safety controls that psychedelic trials need (Johnson et al., 2008).

The Lykos Phase III MDMA-for-PTSD trial shows the trade-off. Investigators excluded participants with uncontrolled hypertension, serious medical disorders, prolonged QT intervals, a history of hyponatremia or hyperthermia, substance use disorders, and excessive or recent MDMA use (NLM, 2018-2020). Those criteria protect participants and trial integrity. They also narrow the evidence base for patients with more complex real-world profiles.

The next step is not to remove safety criteria. It is to explain them, measure who is excluded, and build follow-up studies for the patients most likely to appear in practice. That makes the evidence base more useful for reimbursement and clinical guidance.

Participant motivation and psychedelic hype

Public enthusiasm can shape trial recruitment. High expectations can affect engagement and placebo response. Patients who enrol after exhausting standard options may also carry higher risk if they do not improve. Prior psychedelic experience can influence response too. These factors limit how confidently trial findings can be generalised to routine care (Aday et al., 2022; Noorani & Mathukumaraswamy, 2023).

Feed-forward effects on regulators and payers

Target-population choices follow the product into reimbursement. A smaller, treatment-resistant population can lower budget impact and make early coverage more plausible. It can also create a later evidence gap if clinicians, patients, or sponsors seek broader use.

Inclusion of diverse populations

Psychedelic trials have also struggled to recruit demographically representative samples. A recent review found that about 85% of participants identified as non-Hispanic White, while Black, Hispanic/Latino, and Asian participants represented 2.9%, 5.9%, and 3.2%, respectively (Hughes & Garcia-Romeu, 2024). Some MDMA studies have improved this pattern, including Mitchell et al. (2023), where 33.7% of participants were non-White, but representation remains uneven.

Improving representation requires practical design choices, not just better intent. Trials may need paid travel, flexible scheduling, multilingual materials, community partnerships, and sites that people trust. In Europe, this also means planning for immigrant communities and ethnic minorities that are often underrepresented in research (Noorani & Mathukumaraswamy, 2023; Haft et al., 2024).

Clinical evidence generation

Efficacy outcomes

Primary and secondary endpoints

Psychedelic clinical trials measure success through specific outcomes called endpoints. The main (primary) endpoints typically look at how well symptoms improve or resolve, for example, tracking depression scores in TRD or anxiety levels in generalised anxiety disorder (GAD). Researchers measure these improvements using standard rating scales like the Montgomery–Åsberg Depression Rating Scale (MADRS) for depression or the Clinician-Administered PTSD Scale (CAPS) for PTSD.[14]2

For example, a Phase II psilocybin trial in treatment-resistant depression used three-week changes in MADRS scores as the primary endpoint. Secondary endpoints tracked response and remission (Goodwin et al., 2022).

While symptom reduction remains the primary focus, psychedelic trials may be suitable candidates for measuring secondary outcomes like quality of life (QoL) and functional improvements using tools such as the World Health Organization Quality of Life questionnaire. However, in most cases, regulators and payers prefer clear, symptom-based outcome measures (EMA, 2006).

The disconnect between endpoints and psychedelic effects

Psychedelic trials may capture benefits that symptom scales do not fully reflect. For example, remission on MADRS is clinically meaningful, but it may miss changes patients describe in purpose, emotional clarity, relationships, or daily function. Critics argue that relying only on symptom scores can understate some patient-relevant effects of psychedelic therapy (Grunder et al., 2024).

Trials should pair symptom scales with measures of daily function, quality of life, work or study participation, and sustained recovery where those outcomes matter for the access case. Symptom improvement remains central, but it is rarely the whole value story.

Regulatory and payer perspectives on endpoint selection

HTA bodies look for benefits that matter in real services: durable remission, functional recovery, fewer relapses, lower downstream care use, and sometimes productivity effects. Developers therefore need endpoints that satisfy regulators without leaving payers to build the economic case from weak secondary evidence.

In contrast, HTA bodies focus on endpoints that reflect real-world benefits, such as functional recovery and productivity improvements. For example, achieving sustained remission and demonstrating long-term cost offsets would be highly influential factors supporting reimbursement. This dynamic creates tension in endpoint selection: developers must balance the need to satisfy regulatory requirements for efficacy with the evidence payers require to demonstrate economic and societal value.

Future directions for endpoints in psychedelic trials

Traditional endpoints capture only part of the psychedelic therapy value case. Trials should include patient-reported outcomes on well-being, life satisfaction, connectedness, and function alongside symptom reduction when those claims will matter for access.

Validated secondary endpoints can help bridge this gap. Quality-of-life, functioning, caregiver burden, and productivity measures should be chosen early, collected consistently, and connected to the economic model rather than added as decorative outcomes.

Duration of effect

Duration of effect is central to the access case. A high-cost, staff-intensive treatment is easier to justify if benefits last. The problem is that long-term follow-up often mixes drug effect with later therapy, peer support, medication changes, and repeat treatment.

Evidence for long-term efficacy

Some studies report sustained symptom reductions in depression, PTSD, anxiety, and addiction. In one psilocybin study in treatment-resistant depression, response and remission rates were 75% and 58% at 12 months (Gukasyan et al., 2022). A six-month comparison with escitalopram found sustained improvement in both groups, with stronger psychosocial gains for psilocybin on some measures (Erritzoe et al., 2024).

Early studies also show that a single psychedelic experience can remain meaningful to participants for years. In the Good Friday Experiment, psilocybin participants still described lasting spiritual and personal meaning 27 years later (Doblin, 1991). In PTSD, MDMA therapy follow-up data showed gains lasting up to 74 months, although 26% of participants sought additional therapy and 10% reported using MDMA outside the trial (Mithoefer et al., 2013; Jerome et al., 2020).

Other long-term findings are promising but varied. LSD-assisted therapy has shown anxiety and depression reductions lasting up to 94 weeks (Holze et al., 2024). Psilocybin studies in cancer-related distress and smoking cessation have reported durable benefits in selected groups, but many datasets are small, open-label, or drawn from highly supported research settings (Agin-Liebes et al., 2020; Johnson, Garcia-Romeu & Griffiths, 2017).

Role of additional interventions

Long-term follow-up often shows that patients use other forms of support after psychedelic treatment. Jerome et al. (2020) reported that some PTSD participants sought further treatment. Participants in a psilocybin trial for treatment-resistant depression described using peer support, additional therapy, or microdosing to maintain gains (Breeksema et al., 2024).

Psychedelic interventions may start the change process, but long-term benefit can depend on follow-up therapy, peer support, or other care. Trials and economic evaluations often miss those supports. For payers, that makes durability and cost-effectiveness harder to interpret.

Differences between trials and real-world implementation

Trial conditions can make outcomes look stronger or more durable than routine care. Participants often receive careful screening, intensive support, motivated clinicians, and structured follow-up. In the psilocybin-escitalopram comparison, both groups received psychological support, which differs from routine antidepressant prescribing in many systems (Erritzoe et al., 2024).

Real-world services may need retreatment or step-up support. Ketamine evidence already shows that some patients relapse and may benefit from re-induction protocols (Castro et al., 2024). Some psilocybin trial participants have also said one session was not enough for lasting change (Breeksema et al., 2024).

Repeated treatments and cost-effectiveness

Limited redosing evidence makes cost-effectiveness modelling harder. Some MDMA-for-PTSD models treat the intervention as a one-time cost with long-term savings, but follow-up studies and patient reports point to possible periodic treatment, peer support, or adjunctive care (Marseille et al., 2022). Classical psychedelic evidence is still often small or open-label. Ketamine shows the opposite issue: benefits can be short-lived, so maintenance protocols become central to access planning (Price et al., 2023).

Regulatory considerations

Regulators and payers both need durability data, but they use it differently. Regulators look for sustained efficacy and safety over clinically meaningful timeframes. Payers need to know how long benefit lasts, whether booster sessions are needed, and what follow-up care should be funded. Short primary-endpoint windows of 6 to 12 weeks may not answer those questions.

Safety and tolerability

Acute adverse events

Most adverse events in psychedelic trials are transient and manageable, but reporting is still inconsistent. A meta-analysis of 214 studies found serious adverse events in about 4% of participants with pre-existing neuropsychiatric disorders, while only 23.5% of studies used systematic adverse-event assessment methods (Hinkle et al., 2024). For HTA bodies, the gap is not only safety; it is the quality and consistency of safety reporting.

Psychedelic therapies often involve one or a few dosing sessions rather than daily medication. That may reduce chronic exposure, but it shifts the safety question toward acute monitoring, psychological risk, drug interactions, and what happens after the session.

Healthcare systems also need trained staff during dosing. Acute anxiety, dysphoria, or paranoia require supervision during sessions. MDMA can produce cardiovascular effects that need medical oversight, while ibogaine carries more serious cardiac risks and requires specialised monitoring (Makunts et al., 2023; Ona et al., 2021).

Drug interactions remain under-studied, especially with common psychiatric medicines. Some combinations appear safe; others can change the therapeutic effect or safety profile, making tapering decisions harder before treatment (Becker et al., 2022; Halman et al., 2023). FAERS data have surfaced adverse events not always captured in trials, including flashbacks and increased suicidal ideation, which strengthens the case for post-marketing surveillance (Jiang et al., 2023; Gastaldon et al., 2020).

Long-term safety also includes what happens after the immediate adverse event window. Some patients return to conventional treatment or need ongoing support (Jerome et al., 2020; Gukasyan et al., 2022). Researchers have also documented rare persistent perceptual symptoms such as HPPD, which are often mild in controlled settings but still need clear monitoring and reporting (Ford et al., 2022; Zhou et al., 2022).

For access, safety evidence has to translate into service design: who screens patients, who monitors dosing, what emergency procedures exist, and how long follow-up continues. Those details affect staffing, liability, cost, and whether clinics can deliver care reliably.

Real-world evidence (RWE)

Postmarketing surveillance

Post-marketing surveillance will show how psychedelic therapies perform outside controlled trials. These studies can collect real-world evidence from different clinics, patient groups, and delivery models. That matters because setting, therapist experience, patient selection, and comorbidities may all affect outcomes.

Regulators already use real-world evidence across the product lifecycle. The EMA does this through initiatives such as DARWIN EU (EMA, n.d.). In the United Kingdom, NICE uses real-world data to address uncertainty in clinical evidence and support patient-access decisions.

How RWE supports efficacy and safety claims

Real-world evidence is especially useful for questions trials often leave open: long-term benefit, rare safety events, use in patients with comorbidities, and outcomes in underrepresented groups. Ketamine implementation has already produced post-approval evidence through observational studies and registries, helping clarify use patterns and safety monitoring (e.g. Alnefeesi et al., 2022; Martinotti et al., 2022). Psychedelic therapies need similar registries and follow-up systems.

Regulatory and payer perspectives

For payers, real-world evidence can reduce uncertainty after launch. Registries and post-authorisation studies can track durability, retreatment, adverse events, resource use, and outcomes in patients who would not qualify for tightly controlled trials. That evidence is especially important if coverage starts with conditions, registries, or managed-entry agreements.

Engage the stakeholders who will judge the evidence

Engaging regulators

The EMA supports EU regulatory development through Scientific Advice Meetings and early dialogue. Developers can use these routes to discuss trial design, dose-response work, and regulatory expectations. EMA has acknowledged psychedelics in draft depression treatment guidance, but Europe still lacks a dedicated psychedelic drug-development guideline (EMA, 2023b).

The April 2024 Multi-stakeholder Workshop on Psychedelics - Towards an EU Regulatory Framework stressed early engagement with regulators (EMA, 2024). Developers can use Scientific Advice to test quality, clinical, and methodological plans with the EMA. They can also approach the Innovation Task Force or the Scientific Advice Working Party for earlier input. At the time of that workshop, no psychedelic developer had begun formal consultation for a centralised marketing authorisation application in the EU, leaving a clear alignment gap.

EMA advice can clarify dose-response work, durability, concomitant medication handling, and trial methods. It is less likely to settle the full therapy-delivery question, because drug regulators mainly review the medicinal product. Developers therefore need parallel plans for the medicine, the support protocol, and the evidence payers will use after approval.

The Spravato (esketamine) development experience, discussed during the 2024 EMA meeting, showed why site selection, recruitment strategy, and blinded assessments matter when expectancy effects are likely. Psychedelics face the same issue, with added media attention and patient expectations. Early regulatory dialogue helps, but approval does not guarantee reimbursement. Regulators and payers often need different evidence, so development plans should account for both from the start.

The pathway to market authorisation also has timing constraints. The EMA's centralised evaluation lasts 180 days, while accelerated assessment can reduce the target timeline to 120 days (EC, 2023a).[15]3 PRIME and the Innovation Task Force give developers additional ways to engage early, especially for therapies aimed at unmet medical needs. Early dialogue helps developers plan for approval, but they still need to design evidence packages that payers can use after authorisation.

Working with payers and HTA bodies

Early engagement with payers and HTA bodies should shape clinical development, not merely follow it. Psychedelic therapies combine a medicine with psychological and service components, so trials need evidence on clinical effect, durability, safety, resource use, and quality of life.

Developers should consider head-to-head Phase III trials against standard treatments, such as SSRIs or psychotherapy alone, because HTA bodies will need comparative effectiveness evidence. Patient-reported outcomes should also be built into the programme, especially measures tied to function, durable remission, and quality of life. The Spravato experience shows that comparator and endpoint choices can support approval while also shaping later reimbursement decisions.

EMA parallel consultations with HTA bodies can help align trial design with later payer requirements. These discussions can clarify patient populations, endpoints, comparators, and evidence-generation plans before protocols become expensive to change.

Involving patient advocacy groups

Patient groups can improve trial design before protocols are locked. PsyPAN brings prior trial participants into discussions about safety, consent, communication, and participant experience. PAREA connects access, research, and policy perspectives across Europe. Both can help developers spot practical barriers that may not appear in regulator-focused plans.

Indication-specific advocacy groups add another layer. They can help choose patient-reported outcomes, identify barriers to participation, and improve recruitment and retention. Their input is especially useful when trials need more representative samples and outcomes tied to daily life rather than symptom scores alone.

What this means for access

Clinical development choices become access choices. Comparator selection, exclusion criteria, follow-up duration, support protocol, safety monitoring, and patient-reported outcomes all affect whether payers can judge value after approval.

For developers, the safest late-stage plan is not simply the trial most likely to show efficacy. It is the evidence package that can survive regulatory review, HTA scrutiny, service-cost modelling, and patient access questions in the countries that matter most.